Mycoplasma Testing Segmentation
Application (Cell Line, Virus Testing, End of Production Testing)
The cell line segment is estimated to gain the largest market share of about 55% in the year 2037. The growth of the segment is expected due to the rising demand for monoclonal antibodies. For instance, monoclonal antibodies have been proven efficient in constraining COVID-19. Anti-SARS-CoV-2 monoclonal antibodies, such as REGEN-COV, have gained success to prevent infection in domestic contacts and to reduce the risk of hospitalization or death associated with COVID-19. Testing cell lines used for monoclonal antibod production ensures the prevention of mycoplasma contamination and interference with cell growth and antibody expression.
Technique (PCR, ELISA, Microbial Culture, Enzymatic Methods)
The PCR segment is expected to garner a tremendous share of around 40% in the year 2037. The PCR technique recognizes the various species of mycoplasma by isolating the additional contaminated DNA. The results gained by the PCR (polymerase chain reaction) technique are highly reliant, moreover, the results are quick to achieve and the technique is easy to use.
Our in-depth analysis of the market includes the following segments:
|
Application |
|
|
Technique |
|
|
Product & Services |
|
|
End User |
|
